NovoCure Ltd (NVCR) Quote

NovoCure’s Phase 3 PANOVA-3 trial evaluated TTFields combined with nab-paclitaxel and gemcitabine for locally advanced pancreatic cancer. Final results released in December 2024 showed the trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival. Additional data will be presented at the ASCO Annual Meeting on May 31, 2025, reinforcing the potential expansion of TTFields into this high-mortality indication.

And you, Galzus Research, keep proving that someone, some outfit, is paying you..
Here is why...
When an author writes an investigational report, It is usually based on skillful/unbiased interpretation of the data, It is peer REVIEWED, and the said Author sign it Very Proudly & Confidently, WITHOUT APPARENT FEAR, by Putting His/her Name on it...

As you might have NOTICED, Your Work is a "NOONE, NONAME WORK"..!!!!

Beside that, the said Morally Responsible Author doesn't spend 24/7 on the MB, where the paper is written about, TRYING TO CONVINCE INVESTORS/READERS that he is Absolutely correct (over & over & over again) about his OPINION (as yours is just that) that the technology/company he has written about not worth considering as an investment option!!

And your response in the post below "Why would Novocure be afraid of a treatment that absolutely is not getting approved in the US, because the company hasn't bothered to file" shows how NAIVE YOU ARE in your assessment as, If you have not also NOTICED, we live in a Global Society & Approval Anywhere WILL negatively Impacting competing therapeutic Contenders/Pretenders..!!

Lastly, you might be correct that Novocure has not directly paid you, but in my opinion, other Parties with vest interest might have....

Take care & keep pushing your Opinion piece!!

P.S. I MIGHT HAVE HIT THE NAIL ON THE HAED AS YOU CALLED ME THIS .... "You are about the dullest tack in the drawer, it would seem"

Again, take care & good luck.. !!
.

But Should rember, You Have Been Calling WOLF too many times!!

Truth hurts.
You have research skills? Don't flatter yourself. I do know you have BS. Your pathetic record is a perfect illustration of my point.
Keep playing. That's the only way you feel relevant.

Insults really do add to your credibility.

Professionals stopped publishing responses related to DCVax as soon as they stopped publishing meaningful studies that had the chance to change the standard of care. Contrary to what you may think, the vast majority of oncologists, even those in the neuro-oncology space, aren't thinking about dendritic cell vaccination as a particularly attractive way forward.

In short, the critics stopped publicly commenting on it because it stopped being a topic of conversation within a few months of being published. Just like most studies that don't lead to an FDA submission. Note that no one has commented, positively or negatively, on the pilot trial with poly-ICLC.

So instead of sputtering uselessly about your opinion on my research skills, you could do some work to refute things I've said. Then I would respond to you again. As for now, that's all you'll get from me. Listen or don't.

You don't know how to do extensive literature review, do you? I don't blame you since you are a fake Ph.D.

You know why all those naysayers from medical field stopped publishing papers attacking DCVax-L after the publication of the following paper. They are the real Ph.D and they know massive and sustainable t-cell infiltration into the most difficult tumor site is real. You are such a lightweight as reflected by your pathetic record. Normally I don't deal with lightweight. Today is your lucky day.

https://www.nature.com/articles/s41467-024-48073-y

How much do you think Novocure paid me to write about NWBO? Why would Novocure be afraid of a treatment that absolutely is not getting approved in the US, because the company hasn't bothered to file?

You are about the dullest tack in the drawer, it would seem.

This Noname Guy/Girl, Galzus Research, has written a bash post against NWBO & he has been on their MB 24/7 trying to convince investors that he knows what he is talking about.... hummmmm.. ????

And he has been repeatedly posting Supportive sStatement on behalf of NVCR...
HAS HE BEEN PAID BY NVCR FOR HIS noName ANTI-NWBO PUBLICATION??
HE actions seems to support that view?? ....
Below is he just posted there
---------------------------------------------

Galzus Research

Re: improving post# 766066

Tuesday, May 06, 2025 8:55:56 AM

Post#
766069
of 766069
A real-world study shows that 5-year OS with tumor-treating fields is around 17%. Do you feel similarly enthusiastic about TTF here?

The only Pivotal for Optune is...., Optune has been, Is, & Remain OUT of TUNE to be Effective...

Not as Advertised!!!

A very bad day for $NVCR but all is not lost! I'm transferring all shares to ten of my favorite charities all are still in the money don't you know. Wishing everyone much peace, happiness! GLTA

KEYNOTE-D58 is a pivotal trial (N=741) of Optune concomitant with temozolomide plus keytruda in ndGBM. The estimated primary completion date is April 2029.

Data from the PhII 2-THE-TOP trial https://www.onclive.com/view/temozolomide-pembrolizumab-plus-ttfields-leads-to-tumor-control-in-newly-diagnosed-glioblastoma

dennisbabe - You are not smart enough to be impactful one way or another..
You are just one irrelevant poster.....

LOL - Garbage post....

thank you very much for sharing jondoeuk!

It is a pilot trial, but mPDAC is the largest category at diagnosis. Depending on the data (and if a pivotal trial ends up being successful), TTFs could eventually be used across all diagnosis categories.

Wishing a Happy New Year to everyone who is invested in $NVCR!

dennisdave, you & FeMike are made for each other. The two Irrelevant Scam Artistwannabies, begging for attention..

You are both piles of SSSSSSSSSSSSS.......HIT....

And you jondickuk, crawling around to save your clients from bad advise you capable of giving..

LOL....

$NVCR has reached its 52-week high! Wishing everyone a great weekend! GLTA

Thank you for sharing!
They seem to believe this makes it to market in CRC is my read.

A phase 2 trial, PANOVA-4, will test TTFields combined with a triplet regimen of gemcitabine, nab-paclitaxel and atezolizumab as a first-line treatment for metastatic pancreatic ductal adenocarcinoma. It has completed enrolment and the company said it expects to have data in 2026.

The primary endpoint is disease control rate (DCR). Secondary endpoints include, overall survival (OS), progression-free survival (PFS), 1-year OS rate, objective response rate (ORR), PFS at 6 months, duration of response, and safety.

$NVCR what a great way to kick off December, don't you know? Where are all the bloody naysayers today? We're raising a lot of money for charity! GLTA

Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets; Zai Lab plans to file for regulatory approval in China https://www.businesswire.com/news/home/20241202363277/en/Zai-Lab-and-Novocure-Announce-Positive-Topline-Results-from-Phase-3-PANOVA-3-Clinical-Trial-of-Tumor-Treating-Fields-TTFields-Therapy-for-Pancreatic-Cancer

Looking good $30 +
50% 
12:09 PM EST, 12/02/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)NovoCure's (NVCR) shares rose more than 41% in recent Monday trading after the company and Zai Lab (ZLAB) said that their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival.NovoCure (NVCR) plans regulatory filings in the US, EU, Japan, and other major markets, while Zai Lab plans to file for regulatory approval in China, the companies said.

would love to see new session high
data is hot --- Can become SOC

$NVCR back above $20! GLTA

NVCR: One has to be patently BRAIN DEAD to attribute any significance whatsoever to the 1890's-like ELECTRICAL, cure-all, gadgets that this obvious SCAM company promotes!!!

FDA Approves Novocure’s Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer https://www.businesswire.com/news/home/20241015381082/en

Lovely action AH $NVCR! I can't wait for the opening bell, wishing everyone a great evening! GLTA

$NVCR great way to end the trading day! GLTA

I own both $NVCR and $NWBO, all proceeds will go to charity. GLTA

Glad to see you are in the right stock, NWBO, now!!

Who is the bag holder now???

Going to single digits

Come fly with me, let's fly let's fly away! Ol blue eyes, what a beautiful voice! Great start $NVCR! GLTA

Back above $20 $NVCR! GLTA

Another week, another beautiful day for $NVCR shareholders! GLTA

Another beautiful start of the week for $NVCR! GLTA

LOL - Go from over $200 to $20.
Wondering why this charity worker is NWBO hater.
Wondering why a self proclaimed good spirit tries so hard to destroy a great cancer therapy company. NWBO, hat is not NVCR??
A true charity worker expected to be compassionate, caring, and greatful of all possible potentials...

BUT not this guy??

You judge!!!

KARMA!!

GO $NVCR GO! We're making A LOT of $$$$$ for charities don't you know? GLTA

Beautiful day $NVCR! GLTA

It's been another great week for $NVCR! Have a wonderful weekend everyone! GLTA

Insiders to sell shares in 30 days

LOL 🤣🤣🤣

Or you can simply wait.

Well that's fantastic mate! Perhaps I'll have my lawyer contact her, have a great weekend! GLTA

By now, you should be smart enough to know that Laura Posner or Elliott Leary would be able to get IP address of each poster on NWBO board.

libel? Which part is libel? Nemesis18's post style is very similar to yours, would you agree?

No, do you? GLTA

I'd be careful you're getting a wee bit close to libel don't you know? GLTA

Great way to end the week! Finish strong $NVCR! Have a great weekend everyone! GLTA